Over long-term, gastric bypass surgery associated with higher rate of diabetes remission

September 18, 2012

Severely obese patients who had Roux-en-Y gastric bypass surgery had significant weight loss that was sustained for an average of 6 years after the surgery and also experienced frequent remission and lower incidence of diabetes, hypertension, and abnormal cholesterol levels, compared to participants who did not have the surgery, according to a study in the September 19 issue of JAMA, and theme issue on obesity.

Ted D. Adams, Ph.D., M.P.H., of the University of Utah School of Medicine and Intermountain Healthcare, , presented the findings of the study at a JAMA media briefing.

"The prevalence of extreme obesity in the United States is increasing at a rate greater than . Unfortunately, lifestyle therapy is generally insufficient as a weight management intervention for patients who are extremely obese. To date, effective long-term through pharmacological therapy has been marginal, leaving bariatric as the only providing substantial, long-term weight loss for most patients who are severely obese. For this high-risk population, however, the number of studies reporting long-term weight loss following bariatric surgery are limited and generally have incomplete follow-up," according to background information in the article.

Dr. Adams and colleagues conducted a study to examine the association of Roux-en-Y gastric bypass (RYGB) surgery with weight loss, , and other health risks 6 years after surgery. The study included 1,156 severely obese ( [BMI] 35 or greater) participants, ages 18 to 72 years (82 percent women; average BMI, 46) who sought and received RYGB surgery (n = 418), sought but did not have surgery (n = 417; control group 1), or who were randomly selected from a population-based sample not seeking (n = 321; control group 2).

At 6 years, 92.6 percent (387/418) of the surgical group had follow-up data. Average unadjusted weight loss in the surgical group was 27.7 percent from the beginning of the study to year 6. Weight gain from baseline to year 6 was 0.2 percent in control group 1 and 0 percent in control group 2. "At 2 years, 99 percent of surgical patients had maintained more than 10 percent weight loss from baseline and 94 percent had maintained more than 20 percent weight loss. At 6 years, 96 percent of surgical patients had maintained more than 10 percent weight loss from baseline and 76 percent had maintained more than 20 percent weight loss," the authors write.

The 6-year RYGB surgery group diabetes remission rates were significantly higher than the 2 control groups (62 percent for RYGB surgery group; vs. 8 percent for control group 1; and 6 percent for control group 2). At the same time, diabetes incidence in the RYGB surgery group was significantly lower than in the 2 control groups (2 percent vs. 17 percent and 15 percent; respectively). Remission rates of hypertension and low HDL-C levels at year 6 remained significantly improved in the RYGB surgical group compared with the 2 control groups, with similar improvements observed with remission rates for high LDL-C levels and high triglyceride levels. The numbers of participants with bariatric surgery-related hospitalizations were 33 (7.9 percent), 13 (3.9 percent), and 6 (2.0 percent) for the RYGB surgery group and 2 control groups, respectively.

The authors write that metabolic and cardiovascular risk profiles during the 6 years of follow-up remained significantly improved after RYGB surgery. "In contrast, cardiovascular and metabolic status of severely obese control participants generally worsened during the 6-year period."

"These findings are important considering the rapid increase in total numbers of bariatric surgical operations performed in the United States and worldwide, and may have significant ramifications for the projected 31 million U.S. individuals meeting criteria for bariatric surgery."

In an accompanying editorial, Anita P. Courcoulas, M.D., M.P.H., of the University of Pittsburgh Medical Center, writes that an "important aspect of these findings is that despite the attenuation [lessening] of weight loss between 2 and 6 years in the RYGB group, the control of comorbid conditions remained very good."

"These findings are important because they show in a RYGB cohort and control group with nearly complete follow-up at 6 years that weight loss and associated health benefits following RYGB are durable. The mortality rates in this study were too small to assess statistically, but serve as a reminder of an uncommon but important outcome needing objective monitoring."

Explore further: Type 2 diabetes cured by weight loss surgery returns in one-fifth of patients

More information: JAMA. 2012;308[11]:1122-1131. and JAMA. 2012;308[11]:1160-1161.

Related Stories

Type 2 diabetes cured by weight loss surgery returns in one-fifth of patients

June 25, 2012
A new study shows that although gastric bypass surgery reverses Type 2 diabetes in a large percentage of obese patients, the disease recurs in about 21 percent of them within three to five years. The study results will be ...

Bariatric surgery dramatically outperforms standard treatment for type 2 diabetes

March 26, 2012
In the first published study of its kind, researchers from the Catholic University/Policlinico Gemelli in Rome, Italy, and NewYork-Presbyterian/Weill Cornell Medical Center found that bariatric surgery dramatically outperforms ...

Bariatric surgery associated with reduction in cardiovascular events and death

January 3, 2012
Among obese individuals, having bariatric surgery was associated with a reduced long-term incidence of cardiovascular deaths and events such as heart attack and stroke, according to a study in the January 4 issue of JAMA.

Bariatric surgery among older, high-risk patients not associated with reduced mortality

June 13, 2011
The use of bariatric surgery among older, severely obese patients was not associated with a decreased risk of death, according to a study in the June 15 issue of JAMA. This study is being released early online to coincide ...

Recommended for you

Controlling diabetes with your phone might be possible someday

November 21, 2017
Think about this. You have diabetes, are trying to control your insulin levels and instead of taking a pill or giving yourself an injection, you click an app on your phone that tells your pancreas to bring blood sugar levels ...

Insulin pill may delay type 1 diabetes in some

November 21, 2017
(HealthDay)—It's often said that timing is everything. New research suggests this may be true when giving an insulin pill to try to prevent or delay type 1 diabetes.

Simple test predicts diabetes remission following weight loss surgery

November 21, 2017
A new simple test that helps predicts which people with type 2 diabetes will benefit most from weight loss surgery has been developed by a UCL-led team.

Pre-diabetes discovery marks step towards precision medicine

November 20, 2017
Researchers from the University of Sydney's Charles Perkins Centre have identified three specific molecules that accurately indicate insulin resistance, or pre-diabetes - a major predictor of metabolic syndrome, the collection ...

Scientists reverse diabetes in a mouse model using modified blood stem cells

November 15, 2017
Researchers at Boston Children's Hospital have successfully reversed type 1 diabetes in a mouse model by infusing blood stem cells pre-treated to produce more of a protein called PD-L1, which is deficient in mice (and people) ...

Pregnancy-related conditions taken together leave moms—and dads—at risk

November 14, 2017
Research has already shown that women who develop either diabetes or high blood pressure during pregnancy are at risk of getting type 2 diabetes, high blood pressure or heart disease years later. Now, a new study from a team ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.